Fondaparinux Market – By Product Type, By Application, By Distribution Channel – Global Forecast 2025 – 2034

Fondaparinux Market Size

The global fondaparinux market size was valued at USD 691.9 million in 2024 and is expected to reach USD 1.32 billion in 2034, growing at a CAGR of 6.8% from 2025 to 2034. Fondaparinux is an anticoagulant utilized in the prevention and treatment of blood clots such as deep vein thrombosis (DVT) and pulmonary embolism (PE).
 

Its mechanism of action is through blocking factor Xa, a protein responsible for blood clot formation, which reduces the risk of clots developing in the body. Fondaparinux is easier to use as it is more targeted action in comparison to heparin. It is injected subcutaneously and can be administered once a day and does not require routine blood tests.
 

The global need for anticoagulant therapies such as fondaparinux is rising due to the surge in the incidence of thromboembolic diseases. This surge is being fueled by a greater occurrence of chronic illnesses such as cancer, and cardiovascular disease. Moreover, sedentary lifestyle issues such as obesity and post-surgery complications further increase the risk of DVT and PE. For instance, the Center for Disease Control  and Prevention (CDC) has reported that in the U.S. alone, up to 900,000 people are affected by venous thromboembolism (VTE) annually. VTE is a broader term including both DTE and PE. It is also estimated that 60,000–100,000 deaths are occurring due to VTE. Thus, the market for fondaparinux is estimated to be increasing in the coming years.
 

Additionally, an increase in the elderly global population is an additional contributing factor to the rise in the use of anticoagulant therapies such as Fondaparinux because thromboembolic diseases like deep vein thrombosis (DVT) and pulmonary embolism (PE) are more common in the elderly population. The United Nations (UN) estimated that by the year 2050, the global population of 65 years and older will reach 1.6 billion, which is nearly twice what was recorded in 2021 which was 761 million.
 

With age, multitude of chronic problems, heart disease, cancer, reduced mobility, increase the chances of blood clots, supporting the market growth. In addition, according to the data from National Institute of Health (NIH), VTE occurs in about 1 in 1,000 people every year. Thus, owing to an increasing aging population worldwide, the market for fondaparinux is expected to rise.
 

 Fondaparinux Market Trends

• The authorities are using real-world data and adverse event tracking systems to identify any potential safety concerns that need further exploration or treatment guideline modifications. The FDA Adverse Event Reporting System (FAERS) is actively capturing adverse event information associated with Fondaparinux use and is continually updating its safety profile. Healthcare professionals and patients are contributing through reporting adverse events as part of the ongoing pharmacovigilance program.
   
• The increase in available anticoagulants has shifted the focus of healthcare providers and researchers to conduct more studies to identify the best treatment options. These studies contribute to better clinical decision-making and optimization of patient care. For instance, Fondaparinux is currently being studied against other anticoagulants, especially direct oral anticoagulants (DOACs), to assess its safety and efficacy. Research on drug–drug interactions of the DOACs is critical to understanding the implications on the use of Fondaparinux.
   
• The increase in total knee replacement and hip surgeries has boosted the demand for anticoagulant therapies, to prevent postoperative thromboembolic events. According to estimates from Statista, in 2021 Switzerland had the highest rate of hip replacements within the OECD countries, with more than 322 per 100,000 residents.
   
• The traditional uses of Fondaparinux are starting to change, as there are increasing evidence from the real world that support its use in different therapeutic areas. It is being investigated by researchers and clinicians for cases where the use of other anticoagulants is less useful or is associated with greater risks.
   
• For instance, Fondaparinux has been studied over the last ten years for use in bariatric surgery, and individuals with vaccine-induced immune thrombotic thrombocytopenia (VITT). It has also been evaluated as a substitution in some pregnant women that have heparin induced thrombocytopenia (HIT) or that are intolerant to low molecular weight heparin (LMWH). Thus, further clinical research can be carried out to generate additional data, especially in bariatric surgery.
   
• Moreover, more advanced studies might be able to provide better evidence to justify the use of this drug in HIT, particularly in pregnant women, which might help to gain approval for this indication which is currently being used as off-label.
   

Fondaparinux Market Analysis

Based on product type, the market is segmented into branded and generic. The global market for fondaparinux was valued at USD 654.4 million in 2023. The generic segment dominated the market with the largest revenue of USD 439.3 million in 2024.
 

• The generic segment captured largest market because of its low prices, increasing availability, and adoption in both inpatient and outpatient settings. The demand for the drug is surging as healthcare providers and patients look for cheaper alternatives to branded fondaparinux.
   
• This segment has also been aided by the increasing burden of thromboembolic diseases, with long-term anticoagulation therapy being essential for an ever-expanding number of patients. Generics deliver the same value at a lower cost which makes them the drugs of choice for healthcare systems looking to save money.
   
• In addition, the competition in the market increased when multiple manufacturers entered after the patent expiration of Fondaparinux, making the drug more affordable.
   
• For instance, Mylan and Dr. Reddy's Laboratories have introduced their generic versions of Fondaparinux which are cheaper than the branded Arixtra. With increasing regulatory approvals in other regions, the supply of these cheaper drugs continues to increase, thereby driving segmental growth in this market.

Based on application, the fondaparinux market is segmented into deep vein thrombosis, pulmonary embolism, acute coronary syndrome, and other applications. The deep vein thrombosis segment emerged as a dominant segment in the market, accounting for 47.8% of revenue share in 2024 and is expected to reach by USD 631.1 million in 2034.
 

• This is attributed to the increased incidence of DVT especially in older patients as well as those suffering from chronic conditions such cancer which greatly increases the chances of developing thrombosis.
   
• For instance, the American Academy of Orthopaedic Surgeons estimates around 700,000 total knee replacements are done each year across the U.S.
   
• The segment is further enhanced by the drug’s predicted effectiveness in the prevention and treatment of the disease, its predicted dosing, and the absence of standard blood test monitoring that is mandatory with other anti-coagulants.
   

Based on distribution channel, the fondaparinux market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Hospital pharmacies segment accounted for the largest revenue share of 44.8% in 2024.
 

• This segment’s dominance is due to the high occurrence of thromboembolic diseases such as PE and DVT, which generally necessitate hospitalization and the administration of anticoagulants. Fondaparinux is preferred because it has a predictable anticoagulant effect, is cost effective and has fixed dosing and minimal monitoring.
   
• Furthermore, there is increasing use in the hospitals to treat acute coronary syndrome (ACS), which requires immediate action. This trend in hospitals is likely to grow more because of the increase in emergency admissions and the elderly population which leads to a rise in numbers of patients needing anticoagulation.

The U.S. fondaparinux market revenue has increased considerably from USD 232.8 million in 2023 to USD 244.3 million in 2024 and is expected to grow significantly, reaching USD 433.9 million by 2034.
 

• The country has a high rate of orthopedic surgeries such as hip replacements as well as knee replacements. According to the American Academy of Orthopedic Surgeons, more than 450,000 total hip replacements are performed each year in the U.S.
   
• Moreover, critical illnesses as well as aging population are on the rise in the country which necessitate anti coagulation mechanisms, thus fostering the market growth.
   

Europe: The UK fondaparinux market is projected to experience steady growth between 2025 and 2034.
 

• The high prevalence of DVT in the country is a major factor in boosting the market of market. According to British Heart Foundation, approximately 60,000 people develop DVT in the UK annually.
   
• Further, the aging population in the UK is another aiding factor for the expansion of the market since people aged 65 and above are likely to suffer from chronic diseases such as cancer and obesity rate is also expanding, increasing risk of DVT. The UK Parliament stated that 19% of the UK population was aged 65 or over in 2022. Further, this number was projected to increase to 27% by 2072.
   

Asia Pacific: Japan fondaparinux market is poised to witness lucrative growth between 2025 – 2034.
 

• With a significantly aging population, Japan is currently undergoing a drastic demographic shift. According to data from Statista, as of November 2023, around 36.35 million people who live in Japan are aged 65 or over.
   
• This change is expected to augment demand for the drug, especially deep vein thrombosis and pulmonary embolism which is predominant among the older population in Japan.
   
• Moreover, the rising VTE risk is associated with a greater increase in cancer incidence, particularly among the medically and surgically hospitalized patients receiving systemic chemotherapy. The estimations made by the National Cancer Center of Japan in 2022 were 1,019,000 newly diagnosed cancer patients and 380,400 deaths due to cancer.
   

Middle East and Africa: The fondaparinux market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi Arabia is also experiencing an aging population. For instance, the number of people aged 60 and above is expected to rise five times from 2 million (5.9% of the total population) in 2020, reaching 10.5 million by 2050.
   
• Such statistics in the aging population are expected to raise the demand for fondaparinux in coming years.
   

Fondaparinux Market Share

The top four players in the industry, Viatris, Dr. Reddy’s Laboratories, Apotex, and Sandoz, hold approximately 50% of the market share. With these firms investing in new formulations, clinical studies and partnerships with research institutes and healthcare organizations, their value proposition is developing rapidly. Most of the important stakeholders are concentrating on generics manufacturing. Dr. Reddy's Laboratories is known to provide low-cost alternatives for treatment of thrombosis.
 

Newer players such as Aurobindo Pharma, and Lupin Pharmaceuticals are adopting newer pharmaceutical manufacturing technologies and cost-efficient production methods to market their generic Fondaparinux. Their aggressive pricing and global marketing strategies are intensifying competition in the market and promoting the use of Fondaparinux in the developed and developing economies.
 

 Fondaparinux Market Companies

Some of the eminent market participants operating in the fondaparinux industry include:

• Abbott Laboratories
• Alchemia
• Apotex
• Aurobindo
• Dr. Reddy’s Laboratories
• Jiangsu Hengrui Medicine
• Lupin Pharmaceuticals
• Sandoz
• ScinoPharm Taiwan
• Viatris

• Sandoz issues generic fondaparinux sodium. The drug’s economic efficacy is appealing to numerous healthcare providers and patients in more developed Sandoz markets. Sandoz has a good reputation, thus it generates considerable revenue in the market.
   
• Dr. Reddy's Laboratories is a global company and has a strong distribution network. The company operates in more than 20 countries and has a strong presence in the oncology, cardiology, and dermatology fields, selling patented drug alternatives at lower prices including fondaparinux.
   

Fondaparinux Industry News:

• In December 2024, the FDA approved Mylan’s Arixtra (fondaparinux) for the venous thromboembolism treatment in pediatric patients aged 1 year or older, weighing at least 10 kg. This new indication expands Arixtra’s existing approval in adults, which includes prophylaxis for deep vein thrombosis (DVT), treatment of acute DVT, and acute pulmonary embolism. This product launch helped the company enhance its product portfolio.
   
• In September 2020, Mylan N.V. purchased for EU 641.9 million the intellectual property and commercialization rights related to Aspen Pharmacare Holdings Limited's thrombosis business in Europe. The deal enhanced Mylan’s competitive position in the thrombosis drugs market.
   

The fondaparinux market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Branded
• Generic 

Market, By Application

• Deep vein thrombosis
• Pulmonary embolism
• Acute coronary syndrome
• Other applications  

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands 
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE